Enviar búsqueda
Cargar
Endometrial hyperplasia
•
17 recomendaciones
•
1,816 vistas
Aboubakr Elnashar
Seguir
Aboubakr Elnashar
Leer menos
Leer más
Salud y medicina
Denunciar
Compartir
Denunciar
Compartir
1 de 20
Descargar ahora
Descargar para leer sin conexión
Recomendados
Endometrial hyperplasia dr.alajami
Endometrial hyperplasia dr.alajami
’Mohamed Alajami
OVARIAN RESERVE
OVARIAN RESERVE
Aboubakr Elnashar
Recurrent pregnancy loss 1
Recurrent pregnancy loss 1
drmcbansal
Recurrent pregnancy loss panel discussion
Recurrent pregnancy loss panel discussion
Niranjan Chavan
Ovarian hyper stimulation syndrome ohss
Ovarian hyper stimulation syndrome ohss
Dr.Laxmi Agrawal Shrikhande
postpartum collapse
postpartum collapse
tariggally
Gynecologic Tumor Markers
Gynecologic Tumor Markers
waleed shehadat
PREGNANCY OF UNKNOWN LOCATION
PREGNANCY OF UNKNOWN LOCATION
Aboubakr Elnashar
Recomendados
Endometrial hyperplasia dr.alajami
Endometrial hyperplasia dr.alajami
’Mohamed Alajami
OVARIAN RESERVE
OVARIAN RESERVE
Aboubakr Elnashar
Recurrent pregnancy loss 1
Recurrent pregnancy loss 1
drmcbansal
Recurrent pregnancy loss panel discussion
Recurrent pregnancy loss panel discussion
Niranjan Chavan
Ovarian hyper stimulation syndrome ohss
Ovarian hyper stimulation syndrome ohss
Dr.Laxmi Agrawal Shrikhande
postpartum collapse
postpartum collapse
tariggally
Gynecologic Tumor Markers
Gynecologic Tumor Markers
waleed shehadat
PREGNANCY OF UNKNOWN LOCATION
PREGNANCY OF UNKNOWN LOCATION
Aboubakr Elnashar
Endometriosis and Infertility
Endometriosis and Infertility
Sujoy Dasgupta
Endometrial hyperplasia and carcinoma
Endometrial hyperplasia and carcinoma
yuyuricci
fertililty sparing surgeries in gynecological cancers
fertililty sparing surgeries in gynecological cancers
Sreelasya Kakarla
germ cell tumours of ovary
germ cell tumours of ovary
Sreelasya Kakarla
Thyroid diseases in pregnancy
Thyroid diseases in pregnancy
ikramdr01
Secondary amenorrhoea by dr alka mukherjee dr apurva mukherjee
Secondary amenorrhoea by dr alka mukherjee dr apurva mukherjee
alka mukherjee
Adenomyosis associated infertility
Adenomyosis associated infertility
Aboubakr Elnashar
Systemic lupus erythematosus During pregnancy
Systemic lupus erythematosus During pregnancy
Aboubakr Elnashar
Adhesion prevention techniques
Adhesion prevention techniques
Niranjan Chavan
Fertility Preservation for Gynecologic Cancer Patients
Fertility Preservation for Gynecologic Cancer Patients
Jibran Mohsin
Obstetric antiphospholipid antibody syndrome
Obstetric antiphospholipid antibody syndrome
Aboubakr Elnashar
THROMBOPROPHYLAXIS DURING PREGNANCY, LABOUR AND AFTER DELIVERY
THROMBOPROPHYLAXIS DURING PREGNANCY, LABOUR AND AFTER DELIVERY
Aboubakr Elnashar
Endometrial hyperplasia
Endometrial hyperplasia
Kavya Liyanage
Adenomyosis associated infertility: Review of systematic reviews
Adenomyosis associated infertility: Review of systematic reviews
Aboubakr Elnashar
Luteal Phase Defect Contributors Dr.Shweta Mittal Gupta & DGF Team Experts
Luteal Phase Defect Contributors Dr.Shweta Mittal Gupta & DGF Team Experts
Lifecare Centre
Recurrent pregnancy loss
Recurrent pregnancy loss
Dr.Laxmi Agrawal Shrikhande
Medical management of heavy menstrual bleeding hmb
Medical management of heavy menstrual bleeding hmb
Dr.Laxmi Agrawal Shrikhande
Thromboprophylaxis in Obstetrics
Thromboprophylaxis in Obstetrics
Sujoy Dasgupta
Anti-Mullerian Hormone (AMH) -Novel Biomarker & its Applications
Anti-Mullerian Hormone (AMH) -Novel Biomarker & its Applications
Dr. Rajesh Bendre
Management of cesarean scar pregnancy
Management of cesarean scar pregnancy
Osama Warda
Recurrent miscarriage Prof. Aboubakr Elnashar
Recurrent miscarriage Prof. Aboubakr Elnashar
Aboubakr Elnashar
Reurrent Miscarriage
Reurrent Miscarriage
Aboubakr Elnashar
Más contenido relacionado
La actualidad más candente
Endometriosis and Infertility
Endometriosis and Infertility
Sujoy Dasgupta
Endometrial hyperplasia and carcinoma
Endometrial hyperplasia and carcinoma
yuyuricci
fertililty sparing surgeries in gynecological cancers
fertililty sparing surgeries in gynecological cancers
Sreelasya Kakarla
germ cell tumours of ovary
germ cell tumours of ovary
Sreelasya Kakarla
Thyroid diseases in pregnancy
Thyroid diseases in pregnancy
ikramdr01
Secondary amenorrhoea by dr alka mukherjee dr apurva mukherjee
Secondary amenorrhoea by dr alka mukherjee dr apurva mukherjee
alka mukherjee
Adenomyosis associated infertility
Adenomyosis associated infertility
Aboubakr Elnashar
Systemic lupus erythematosus During pregnancy
Systemic lupus erythematosus During pregnancy
Aboubakr Elnashar
Adhesion prevention techniques
Adhesion prevention techniques
Niranjan Chavan
Fertility Preservation for Gynecologic Cancer Patients
Fertility Preservation for Gynecologic Cancer Patients
Jibran Mohsin
Obstetric antiphospholipid antibody syndrome
Obstetric antiphospholipid antibody syndrome
Aboubakr Elnashar
THROMBOPROPHYLAXIS DURING PREGNANCY, LABOUR AND AFTER DELIVERY
THROMBOPROPHYLAXIS DURING PREGNANCY, LABOUR AND AFTER DELIVERY
Aboubakr Elnashar
Endometrial hyperplasia
Endometrial hyperplasia
Kavya Liyanage
Adenomyosis associated infertility: Review of systematic reviews
Adenomyosis associated infertility: Review of systematic reviews
Aboubakr Elnashar
Luteal Phase Defect Contributors Dr.Shweta Mittal Gupta & DGF Team Experts
Luteal Phase Defect Contributors Dr.Shweta Mittal Gupta & DGF Team Experts
Lifecare Centre
Recurrent pregnancy loss
Recurrent pregnancy loss
Dr.Laxmi Agrawal Shrikhande
Medical management of heavy menstrual bleeding hmb
Medical management of heavy menstrual bleeding hmb
Dr.Laxmi Agrawal Shrikhande
Thromboprophylaxis in Obstetrics
Thromboprophylaxis in Obstetrics
Sujoy Dasgupta
Anti-Mullerian Hormone (AMH) -Novel Biomarker & its Applications
Anti-Mullerian Hormone (AMH) -Novel Biomarker & its Applications
Dr. Rajesh Bendre
Management of cesarean scar pregnancy
Management of cesarean scar pregnancy
Osama Warda
La actualidad más candente
(20)
Endometriosis and Infertility
Endometriosis and Infertility
Endometrial hyperplasia and carcinoma
Endometrial hyperplasia and carcinoma
fertililty sparing surgeries in gynecological cancers
fertililty sparing surgeries in gynecological cancers
germ cell tumours of ovary
germ cell tumours of ovary
Thyroid diseases in pregnancy
Thyroid diseases in pregnancy
Secondary amenorrhoea by dr alka mukherjee dr apurva mukherjee
Secondary amenorrhoea by dr alka mukherjee dr apurva mukherjee
Adenomyosis associated infertility
Adenomyosis associated infertility
Systemic lupus erythematosus During pregnancy
Systemic lupus erythematosus During pregnancy
Adhesion prevention techniques
Adhesion prevention techniques
Fertility Preservation for Gynecologic Cancer Patients
Fertility Preservation for Gynecologic Cancer Patients
Obstetric antiphospholipid antibody syndrome
Obstetric antiphospholipid antibody syndrome
THROMBOPROPHYLAXIS DURING PREGNANCY, LABOUR AND AFTER DELIVERY
THROMBOPROPHYLAXIS DURING PREGNANCY, LABOUR AND AFTER DELIVERY
Endometrial hyperplasia
Endometrial hyperplasia
Adenomyosis associated infertility: Review of systematic reviews
Adenomyosis associated infertility: Review of systematic reviews
Luteal Phase Defect Contributors Dr.Shweta Mittal Gupta & DGF Team Experts
Luteal Phase Defect Contributors Dr.Shweta Mittal Gupta & DGF Team Experts
Recurrent pregnancy loss
Recurrent pregnancy loss
Medical management of heavy menstrual bleeding hmb
Medical management of heavy menstrual bleeding hmb
Thromboprophylaxis in Obstetrics
Thromboprophylaxis in Obstetrics
Anti-Mullerian Hormone (AMH) -Novel Biomarker & its Applications
Anti-Mullerian Hormone (AMH) -Novel Biomarker & its Applications
Management of cesarean scar pregnancy
Management of cesarean scar pregnancy
Similar a Endometrial hyperplasia
Recurrent miscarriage Prof. Aboubakr Elnashar
Recurrent miscarriage Prof. Aboubakr Elnashar
Aboubakr Elnashar
Reurrent Miscarriage
Reurrent Miscarriage
Aboubakr Elnashar
Threatened and unexplained repeated miscarriages
Threatened and unexplained repeated miscarriages
Aboubakr Elnashar
PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015
PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015
Aboubakr Elnashar
FIRST-TRIMESTER SCREENING & PREVENTION OF PET FIGO, 2019
FIRST-TRIMESTER SCREENING & PREVENTION OF PET FIGO, 2019
Aboubakr Elnashar
GESTATIONAL DM
GESTATIONAL DM
Aboubakr Elnashar
ART PREGNANCY COMPLICATIONS
ART PREGNANCY COMPLICATIONS
Aboubakr Elnashar
Patient preparation before IVF
Patient preparation before IVF
Aboubakr Elnashar
Pathophysiology of Infertility
Pathophysiology of Infertility
Jegan Nadar
pre existing DM in pregnancy
pre existing DM in pregnancy
Aboubakr Elnashar
Hormonal assay in clinical gyn
Hormonal assay in clinical gyn
Aboubakr Elnashar
Diagnosis of PCOS MCMCTACONSESSION4.pptx
Diagnosis of PCOS MCMCTACONSESSION4.pptx
DrRokeyaBegum
Recurrent pregnancy loss: interactive session
Recurrent pregnancy loss: interactive session
Aboubakr Elnashar
update on PCOS
update on PCOS
Aboubakr Elnashar
Recurrent pregnancy loss
Recurrent pregnancy loss
drmcbansal
Lecture9
Lecture9
abeer el shabacy
Amenorhea
Amenorhea
Aboubakr Elnashar
Amenorrhea
Amenorrhea
Venkat Ramesh
Prediction of the Syndrome Premature Ovarian Insufficiency
Prediction of the Syndrome Premature Ovarian Insufficiency
ijtsrd
Female infertility and its causes
Female infertility and its causes
LaveinyaBalaji1
Similar a Endometrial hyperplasia
(20)
Recurrent miscarriage Prof. Aboubakr Elnashar
Recurrent miscarriage Prof. Aboubakr Elnashar
Reurrent Miscarriage
Reurrent Miscarriage
Threatened and unexplained repeated miscarriages
Threatened and unexplained repeated miscarriages
PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015
PREMATURE OVARIAN INSUFFICIENCY ESHRE Guidelines, 2015
FIRST-TRIMESTER SCREENING & PREVENTION OF PET FIGO, 2019
FIRST-TRIMESTER SCREENING & PREVENTION OF PET FIGO, 2019
GESTATIONAL DM
GESTATIONAL DM
ART PREGNANCY COMPLICATIONS
ART PREGNANCY COMPLICATIONS
Patient preparation before IVF
Patient preparation before IVF
Pathophysiology of Infertility
Pathophysiology of Infertility
pre existing DM in pregnancy
pre existing DM in pregnancy
Hormonal assay in clinical gyn
Hormonal assay in clinical gyn
Diagnosis of PCOS MCMCTACONSESSION4.pptx
Diagnosis of PCOS MCMCTACONSESSION4.pptx
Recurrent pregnancy loss: interactive session
Recurrent pregnancy loss: interactive session
update on PCOS
update on PCOS
Recurrent pregnancy loss
Recurrent pregnancy loss
Lecture9
Lecture9
Amenorhea
Amenorhea
Amenorrhea
Amenorrhea
Prediction of the Syndrome Premature Ovarian Insufficiency
Prediction of the Syndrome Premature Ovarian Insufficiency
Female infertility and its causes
Female infertility and its causes
Más de Aboubakr Elnashar
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
Aboubakr Elnashar
hepatitis B.pdf
hepatitis B.pdf
Aboubakr Elnashar
hepatitis c2022.pdf
hepatitis c2022.pdf
Aboubakr Elnashar
Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022
Aboubakr Elnashar
Adenxal mass guidelines2020
Adenxal mass guidelines2020
Aboubakr Elnashar
Aesthetic gynecology controversy
Aesthetic gynecology controversy
Aboubakr Elnashar
FIRST TRIMESTER ANC OF IVF
FIRST TRIMESTER ANC OF IVF
Aboubakr Elnashar
Unnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicine
Aboubakr Elnashar
Infertility prevention
Infertility prevention
Aboubakr Elnashar
Individualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulation
Aboubakr Elnashar
Female infertility
Female infertility
Aboubakr Elnashar
Maternal near miss
Maternal near miss
Aboubakr Elnashar
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
Aboubakr Elnashar
cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021
Aboubakr Elnashar
CAESAREAN SCAR DEFECT
CAESAREAN SCAR DEFECT
Aboubakr Elnashar
Management of pregnancy of unknown location
Management of pregnancy of unknown location
Aboubakr Elnashar
Aerobic Vaginitis
Aerobic Vaginitis
Aboubakr Elnashar
COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021
Aboubakr Elnashar
Imaging in pregnancy 2 in1
Imaging in pregnancy 2 in1
Aboubakr Elnashar
PREECLAMPSIA‐ECLAMPSIA SPECTRUM
PREECLAMPSIA‐ECLAMPSIA SPECTRUM
Aboubakr Elnashar
Más de Aboubakr Elnashar
(20)
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
hepatitis B.pdf
hepatitis B.pdf
hepatitis c2022.pdf
hepatitis c2022.pdf
Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022
Adenxal mass guidelines2020
Adenxal mass guidelines2020
Aesthetic gynecology controversy
Aesthetic gynecology controversy
FIRST TRIMESTER ANC OF IVF
FIRST TRIMESTER ANC OF IVF
Unnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicine
Infertility prevention
Infertility prevention
Individualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulation
Female infertility
Female infertility
Maternal near miss
Maternal near miss
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021
CAESAREAN SCAR DEFECT
CAESAREAN SCAR DEFECT
Management of pregnancy of unknown location
Management of pregnancy of unknown location
Aerobic Vaginitis
Aerobic Vaginitis
COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021
Imaging in pregnancy 2 in1
Imaging in pregnancy 2 in1
PREECLAMPSIA‐ECLAMPSIA SPECTRUM
PREECLAMPSIA‐ECLAMPSIA SPECTRUM
Último
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Service
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Service
sonalikaur4
Call Girls ITPL Just Call 7001305949 Top Class Call Girl Service Available
Call Girls ITPL Just Call 7001305949 Top Class Call Girl Service Available
narwatsonia7
Low Rate Call Girls Mumbai Suman 9910780858 Independent Escort Service Mumbai
Low Rate Call Girls Mumbai Suman 9910780858 Independent Escort Service Mumbai
sonalikaur4
Hemostasis Physiology and Clinical correlations by Dr Faiza.pdf
Hemostasis Physiology and Clinical correlations by Dr Faiza.pdf
MedicoseAcademics
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
Miss joya
sauth delhi call girls in Bhajanpura 🔝 9953056974 🔝 escort Service
sauth delhi call girls in Bhajanpura 🔝 9953056974 🔝 escort Service
9953056974 Low Rate Call Girls In Saket, Delhi NCR
Call Girls Service Nandiambakkam | 7001305949 At Low Cost Cash Payment Booking
Call Girls Service Nandiambakkam | 7001305949 At Low Cost Cash Payment Booking
Nehru place Escorts
Call Girl Service Bidadi - For 7001305949 Cheap & Best with original Photos
Call Girl Service Bidadi - For 7001305949 Cheap & Best with original Photos
narwatsonia7
Call Girls Service Noida Maya 9711199012 Independent Escort Service Noida
Call Girls Service Noida Maya 9711199012 Independent Escort Service Noida
Pooja Gupta
Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...
Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...
narwatsonia7
VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknow
VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknow
narwatsonia7
Call Girls Service Chennai Jiya 7001305949 Independent Escort Service Chennai
Call Girls Service Chennai Jiya 7001305949 Independent Escort Service Chennai
Nehru place Escorts
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy Platform
Kweku Zurek
Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service Available
narwatsonia7
VIP Call Girls Mumbai Arpita 9910780858 Independent Escort Service Mumbai
VIP Call Girls Mumbai Arpita 9910780858 Independent Escort Service Mumbai
sonalikaur4
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
narwatsonia7
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...
Miss joya
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking Models
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking Models
sonalikaur4
Housewife Call Girls Hsr Layout - Call 7001305949 Rs-3500 with A/C Room Cash ...
Housewife Call Girls Hsr Layout - Call 7001305949 Rs-3500 with A/C Room Cash ...
narwatsonia7
College Call Girls Pune Mira 9907093804 Short 1500 Night 6000 Best call girls...
College Call Girls Pune Mira 9907093804 Short 1500 Night 6000 Best call girls...
Miss joya
Último
(20)
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Service
Call Girls Thane Just Call 9910780858 Get High Class Call Girls Service
Call Girls ITPL Just Call 7001305949 Top Class Call Girl Service Available
Call Girls ITPL Just Call 7001305949 Top Class Call Girl Service Available
Low Rate Call Girls Mumbai Suman 9910780858 Independent Escort Service Mumbai
Low Rate Call Girls Mumbai Suman 9910780858 Independent Escort Service Mumbai
Hemostasis Physiology and Clinical correlations by Dr Faiza.pdf
Hemostasis Physiology and Clinical correlations by Dr Faiza.pdf
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
sauth delhi call girls in Bhajanpura 🔝 9953056974 🔝 escort Service
sauth delhi call girls in Bhajanpura 🔝 9953056974 🔝 escort Service
Call Girls Service Nandiambakkam | 7001305949 At Low Cost Cash Payment Booking
Call Girls Service Nandiambakkam | 7001305949 At Low Cost Cash Payment Booking
Call Girl Service Bidadi - For 7001305949 Cheap & Best with original Photos
Call Girl Service Bidadi - For 7001305949 Cheap & Best with original Photos
Call Girls Service Noida Maya 9711199012 Independent Escort Service Noida
Call Girls Service Noida Maya 9711199012 Independent Escort Service Noida
Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...
Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...
VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknow
VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknow
Call Girls Service Chennai Jiya 7001305949 Independent Escort Service Chennai
Call Girls Service Chennai Jiya 7001305949 Independent Escort Service Chennai
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy Platform
Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service Available
VIP Call Girls Mumbai Arpita 9910780858 Independent Escort Service Mumbai
VIP Call Girls Mumbai Arpita 9910780858 Independent Escort Service Mumbai
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...
Low Rate Call Girls Pune Esha 9907093804 Short 1500 Night 6000 Best call girl...
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking Models
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking Models
Housewife Call Girls Hsr Layout - Call 7001305949 Rs-3500 with A/C Room Cash ...
Housewife Call Girls Hsr Layout - Call 7001305949 Rs-3500 with A/C Room Cash ...
College Call Girls Pune Mira 9907093804 Short 1500 Night 6000 Best call girls...
College Call Girls Pune Mira 9907093804 Short 1500 Night 6000 Best call girls...
Endometrial hyperplasia
1.
ENDOMETRIAL HYPERPLASIA Guidelines of SOGC, 2019 Prof. Aboubakr Elnashar Benha university hospital, Egypt ABOUBAKR ELNASHAR CONTENTS 1. INTRODUCTION 1. INCIDENCE 2. RISK FACTORS 3. CLASSIFICATION & HISTOPATHOLOGY 2. DIAGNOSIS 1. SYMPTOMS 2. SIGNS 3. INVESTIGATIONS 3. MANAGEMENT 1. WITHOUT ATYPIA 2. WITH ATYPIA 3. IN POLYP ❑ CONCLUSION ABOUBAKR ELNASHAR 3
2.
INTRODUCTION ▪ Incidence ▪ increases with age ▪ 133 per 100 000 woman-years ▪ Rarely seen in women under the age of 30 ▪ Its peak in women aged 50 to 54. ABOUBAKR ELNASHAR ▪ Risk factors 1. Menstrual factors: 1. Older age or postmenopausal status 2. Nulliparity or infertility 3. Early menarche or later menopause 4. Anovulation or PCOS 2. Iatrogenic factors: 1. Unopposed exogenous estrogen therapy 2. Tamoxifen ABOUBAKR ELNASHAR 3. Comorbidities: 1. Obesity: important risk factor 2. DM 3. Hypertension 4. Lynch syndrome
3.
4.
▪ Classification & histopathology In 2014, WHO modified the classification to include only 2 categories: 1. Hyperplasia without atypia 2. Hyperplasia with atypia: ▪ Atypical hyperplasia or ▪ Endometrial intraepithelial neoplasia (EIN). ▪ Health care providers should use the 2014 WHO histopathologic classification of endometrial hyperplasia (strong). ABOUBAKR ELNASHAR
5.
ABOUBAKR ELNASHAR ▪ Hyperplasia without atypia ▪ Not share the same genetic mutations as its counterpart. ▪ Rarely progresses to endo carcinoma (1%−3%) ▪ Can be managed conservatively. ABOUBAKR ELNASHAR ▪ Hyperplasia with atypia ▪ Precursor to type I endom carcinomas as both share a similar profile of genetic alterations and monoclonal growth. ▪ 60% have already developed or will develop endometrial cancer. ▪ More definitive treatment approach
6.
DIAGNOSIS ❑ Symptoms ▪ In premenopausal women: ▪ AUB: ▪ Disturbances in regularity, frequency, duration& heaviness of menstrual bleeding ▪ Intermenstrual bleeding (IMB) ▪ Risk of endom carcinoma is higher with IMB compared with HMB ▪ Postmenopausal bleeding ABOUBAKR ELNASHAR ❑ Physical Findings ▪ Can be normal or ▪ Obesity ▪ Features of PCOS. ▪ Bimanual exam of the uterus ▪ Speculum exam for Pap testing ABOUBAKR ELNASHAR
7.
❑ Investigation: 1. Endometrial tissue sampling ▪ Indication: Any woman with suspected endometrial hyperplasia or endometrial cancer ▪ 40 ys or older ▪ BMI of 30 kg/m 2 or greater (moderate). ▪ No response to medical therapy ▪ Young women based on their risk factors. ▪ Using a Pipelle device in an outpatient setting is the most appropriate first step for diagnosis (strong, high). ABOUBAKR ELNASHAR Endocurette Pipelle
8.
2. Hysteroscopy with directed sampling & curettage ▪ The preferred method of investigation in. 1. Non-diagnostic or benign endometrial sample with remaining high suspicion of endometrial hyperplasia or cancer 2. Cervical stenosis, failed endometrial biopsy 3. Persistent bleeding, or excessive pain/anxiety 4. Recurrent symptoms of AUB after initial observation or medical treatment (strong, high). ABOUBAKR ELNASHAR ▪ Risk of Tumour Spillage ▪ Through Hysteroscopy or Saline Infusion, there were concerns about tumour spillage and cancer upstaging in women previously investigated with hysteroscopy or saline US for endometrial hyperplasia or cancer. ▪ There is no study showing any adverse outcome for patients with a previous endoscopic diagnostic procedure. ▪ Since 2014, peritoneal washing has not been part of the International Federation of Gynecology and Obstetrics staging for endometrial cancer. ABOUBAKR ELNASHAR
9.
MANAGEMENT ▪ Addressing the Risk Factors ▪ Encouraging obese to lose weight. ▪ Correction of those medical conditions (strong, high).. ABOUBAKR ELNASHAR I. ENDOMETRIAL HYPERPLASIA WITHOUT ATYPIA 1. Conservative Management ▪ Supported by 1. Long-term risk for progression to endomet carcinoma≤5% 2. Spontaneous regression rates of 75 to 100%. 2. Hormonal TT ▪ Indication: ▪ Hyperplasia does not resolve with observation ▪ AUB (weak, low). ▪ Majority of cases are successfully managed medically ▪ Hysterectomy is not considered first-line TT & is reserved for specific circumstances (moderate). ABOUBAKR ELNASHAR
10.
1. Levonorgestrel IUD should be 1 st line TT due to: 1. Its effectiveness (81% to 94% regression) 2. Favourable side effect profile (strong, high) 3. It can be kept in place for 5 y in patients showing TT response (strong, moderate). ▪ Treating pre & postmenopausal women ▪ Follow-up by ▪ endometrial sampling ▪ performed with the IU device in place ABOUBAKR ELNASHAR 2. Progrstins: ▪ Low-dose oral (regression rate 67 to72%) and ▪ Injectable progestins (DMP: regression rate after 6 m: 92%) remain an acceptable TT option for endometrial hyperplasia with & without atypia desiring an alternative TT modality (strong, high). ▪ Treating both pre & postmenopausal women ABOUBAKR ELNASHAR
11.
▪ Oral progestins: start on a low dose for a minimum of 6 months. ▪ Assessment of the endometrium Endometrial biopsy (strong, very low). ▪ Mid-therapy after 3 months ▪ 3 w after completion of TT to ensure proper interpretation ▪ Relapse rate is higher in patients ▪ Treated with progestins ▪ Those with a BMI 35 kg/m 2 . ▪ The follow-up duration for those patients should therefore be extended. ABOUBAKR ELNASHAR 3. Aromatase inhibitors ▪ An effective TT option for patients with endometrial hyperplasia without atypia. ▪ Letrozole ▪ comparable effectiveness to megestrol acetate ▪ favourable side effect profile ▪ used in pre & postmenopausal women. ABOUBAKR ELNASHAR
12.
Dydrogesterone 10 mg, 2 tablets twice daily from fifth day of menstruation for 21 days for 6 months ABOUBAKR ELNASHAR 3. Surgical Treatment ▪ Indication: 1. Persistent (fails to regress after 12 months) or Recurrent hyperplasia despite progestin use 2. Progression to atypical hyperplasia or carcinoma 3. Ongoing AUB despite TT 4. Patient preference. 5. Contraindication or intolerance to medical TT 6. Unwillingness to comply with surveillance 7. No desire for future fertility 8. High baseline risk for endometrial carcinoma. ABOUBAKR ELNASHAR
13.
▪ Total hysterectomy with opportunistic salpingectomy, with bilateral oophorectomy in postmenopause & (strong, moderate) & ▪ without oophorectomy in premenopausal women {increased mortality & morbidity associated with removal of the ovaries in young women with benign disease} (moderate). ▪ Surgical approach ▪ Vaginal, laparoscopic,& open approaches are all acceptable {it is considered non-neoplastic entity}, ▪ Vag or laparoscopic route: fewer perioperative complications ABOUBAKR ELNASHAR 4. Endometrial Ablation ▪ There is insufficient evidence to support as first-lineTT except in circumstances where major surgery is contraindicated (low). ▪ Safe option for treatment ▪ Limitation 1. Difficulty in confirming complete destruction of the endometrium. 2. Surveillance can be challenging due to obliteration of the endometrial cavity ▪ Patients should be followed up at regular intervals& investigated if AUB persists or recurs. ABOUBAKR ELNASHAR
14.
II. ATYPICAL ENDOMETRIAL HYPERPLASIA/EIN 1. Hysterectomy & Bilateral Salpingo-oophorectomy ▪ are the recommended TT in pre&postmenopausal {underlying risk of malignancy or progression to endometrial cancer. 60% of patients with EIN already have developed or will develop an invasive endometrial cancer} ▪ Retention of ovaries in premenopausal may be considered (low). ▪ The increased risk of mortality&morbidity associated with bilateral oophorectomy in premenopausal women with benign disease should be discussed thoroughly ▪ TT tailored to each individual. ABOUBAKR ELNASHAR ▪ Laparoscopic hysterectomy is preferred for endometrial hyperplasia as it decreases perioperative morbidity& mortality (high) ▪ Laparotomy limited to cases where this is not feasible. ▪ Laparoscopy vs laparotomy: ▪ fewer perioperative complications, shorter hospital stay, quicker return to normal activity ▪ Survival outcomes are similar ▪ Evaluation of the adnexa& other pelvic structures for signs of invasive disease. {Atypical endometrial hyperplasia is associated with higher risk of underlying carcinoma} ABOUBAKR ELNASHAR
15.
▪ Not recommended: 1. Subtotal hysterectomy & morcellation (strong, low) due to concern about malignancy & dissemination of disease 2. Routine intraoperative frozen section analysis (low) 3. Routine lymphadenectomy (moderate). ABOUBAKR ELNASHAR ▪ Endometrial Ablation is generally avoided in patients with atypical hyperplasia because it is a pre-malignant condition. ABOUBAKR ELNASHAR
16.
▪ Fertility preservation TT of EIN: ▪ Options: 1. Oocyte or embryo cryopreservation prior to hysterectomy with BSO 2. Hysterectomy with ovarian preservation& future use of a surrogate. 3. Medical TT followed by ART ▪ Encourage to maintain a BMI below 30 kg/m 2 , as relapse is much more common in obese patients. ABOUBAKR ELNASHAR ▪ Cancer incidence does not increase when comparing patients undergoing primary hysterectomy& delayed hysterectomy for fertility-sparing purposes. ▪ Infertility TT do not increase the relapse rate of EIN. ▪ LBR associated with conservative TT of EIN: 7- 26% ▪ Pregnancy: lower chance of disease recurrence. ▪ Hysterectomy with BSO is recommended when childbearing is no longer desired {The risk of disease recurrence being high} ABOUBAKR ELNASHAR
17.
2. Medical treatment options & follow-up ▪ Uterine preservation may be considered in 1. Patients who wish to preserve their fertility or 2. Who are medically unfit for surgery. ▪ Counselling: Important ▪ should include 1. Risks of 1. Endometrial cancer higher than stage I (2%) 2. Coexisting ovarian cancer (4%) 3. Death (0.5%) 2. Those outcomes could not easily be predicted by pre- treatment investigations. ABOUBAKR ELNASHAR ▪ Conservative treatment options ▪ Progestins (oral or local) ▪ Aromatase inhibitors, or ▪ GnRHa. ▪ Table shows types of progestins and dosages that can be used in treatment of EIN. ABOUBAKR ELNASHAR
18.
▪ Metformin ▪ May also be added to increase TT effect, even in the absence of metabolic syndrome. ▪ Obesity: lower chance of disease remission. ▪ A trial of 6 months ▪ is generally necessary to see TT response, with a plateau at around 12 months. ▪ Regression rates: 55% to 92% ▪ Recurrence rates: 3% to 55% ABOUBAKR ELNASHAR ABOUBAKR ELNASHAR ▪ Metformin anticancer effect: ▪ Affects endometrial maturation, proliferation& implantation. ▪ Delay estrogen-mediated endometrial proliferation
19.
▪ Endometrial biopsy ▪ Every 3 months until at least 2 negative specimens are obtained. ▪ The highest risk of recurrence in the first 2 ys after treatment cessation ▪ Every 6 months for 2 years and ▪ Every year thereafter until ▪ Risk factors are corrected or ▪ Total hysterectomy with BSO is performed. ABOUBAKR ELNASHAR ▪ Definitive surgical treatment indicated if 1. Progression to carcinoma during follow-up, 2. Hyperplasia fails to regress after 12 months of medical TT 3. Relapses after TT with progestins 4. Continuous AUB despite treatment 5. Decline of surveillance or medical TT ABOUBAKR ELNASHAR
20.
Endometrial Hyperplasia in an Endometrial Polyp 1. Should be treated acc to its histologic classification. 2. Sampling of the background endometrium, even when its hysteroscopic appearance is normal. Why? ▪ Endom hyperplasia either with or without atypia will be found in background endometrium in up to 52% ▪ Risk of concurrent endom cancer in patients found to have an atypical endometrial polyp: 5.6%. ABOUBAKR ELNASHAR ABOUBAKR ELNASHAR TAKE HOME MESSAGE I. Introduction: ▪ Risk factors: obesity is important risk factor ▪ Classification: hyperplasia without atypia & with atypia II. Diagnosis: ▪ Endometrial tissue sampling if suspected end hyperplasia ▪ Hysteroscopy if persistent bleeding III. Management ▪ First line ▪ Without atypia: Hormonal TT ▪ With atypia: Hysterectomy with BSO
Descargar ahora